RxDoctor Payments Data

Victoria Sidell

Family · Colonial Heights, VANPI 1629419858

Payments from drug & device makers

$4,501in general payments, 2019–2025

Across 138 payments — averaging $32.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Novartis$527
  • Boston Scientific$245
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$206
  • Merck$186
  • AstraZeneca$182
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,501100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,501 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$35,596
Medicare patients
264
Services billed
739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$67,565
EntrestoSacubitril/Valsartan21$19,281
BrilintaTicagrelor32$18,840
XareltoRivaroxaban20$17,879
JardianceEmpagliflozin15$12,542
Repatha SureclickEvolocumab13$7,563
Ranolazine ErRanolazine26$2,201
Ezetimibe43$985
Metoprolol Succinate84$870
Rosuvastatin Calcium101$833
Bumetanide18$679
ClopidogrelClopidogrel Bisulfate57$535
Chlorthalidone32$421
Amlodipine Besylate69$377
Carvedilol51$373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$61$67,56568 claims
NovartisEntresto$527$19,28121 claims
AstraZenecaBrilinta$182$18,84032 claims
Johnson & JohnsonXarelto$88$17,87920 claims
Boehringer IngelheimJardiance$177$12,54215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.

Other family in Colonial Heights

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →